Peripheral Biomarkers of Parkinson's disease progression and pioglitazone Effects

David K. Simon, Tanya Simuni, Jordan Elm, Joanne Clark-Matott, Allison K. Graebner, Liana Baker, Susan R. Dunlop, Marina Emborg, Cornelia Kamp, John Christopher Morgan, G. Webster Ross, Saloni Sharma, Bernard Ravina

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Pioglitazone, an oral hypoglycemic agent, recently failed to show promise as a disease-modifying agent in a 44-week phase 2 placebo-controlled study in 210 Parkinson's disease (PD) subjects. We analyzed peripheral biomarkers, including leukocyte PGC-1α and target gene expression, plasma interleukin 6 (IL-6) as a marker of inflammation, and urine 8-hydroxydeoxyguanosine (8OHdG) as a marker of oxidative DNA damage. Baseline or changes from baseline in biomarker levels were not associated with the rate of progression of PD. Pioglitazone did not significantly alter biomarker levels. Other agents that more effectively target these mechanisms remain of potential interest as disease modifying therapies in PD.

Original languageEnglish (US)
Pages (from-to)731-736
Number of pages6
JournalJournal of Parkinson's Disease
Volume5
Issue number4
DOIs
Publication statusPublished - Nov 21 2015

    Fingerprint

Keywords

  • 8-hydroxydeoxyguanosine
  • 8OHdG
  • IL-6
  • PGC-1alpha
  • Parkinsons disease
  • biomarker
  • cytokine
  • inflammation
  • interleukin-6
  • oxidativestress
  • pioglitazone

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Simon, D. K., Simuni, T., Elm, J., Clark-Matott, J., Graebner, A. K., Baker, L., ... Ravina, B. (2015). Peripheral Biomarkers of Parkinson's disease progression and pioglitazone Effects. Journal of Parkinson's Disease, 5(4), 731-736. https://doi.org/10.3233/JPD-150666